Prodeon Medical has secured U.S. Food and Drug Administration 510(k) clearance for its innovative Urocross Expander System. This novel device introduces a non-permanent, retrievable implant for treating lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH). The clearance signals the arrival of a new category of minimally invasive therapy that prioritizes tissue preservation and future treatment flexibility for a widespread condition affecting aging men.
A New Paradigm in BPH Therapy
The Urocross system offers a unique method for managing BPH by remodeling obstructed prostatic tissue without permanent changes. The device is placed using a standard flexible cystoscope and remains in place for up to six months to gently reshape the urethra. Following this period, the implant is fully retrieved, leaving no foreign material behind and preserving all future diagnostic and therapeutic pathways for the patient.
Backed by Rigorous Clinical Evidence
The FDA's decision was based on a comprehensive body of clinical evidence, including the Expander-1 Feasibility Trial and the large-scale Expander-2 Pivotal Trial. The Expander-2 study was a multi-center, randomized controlled trial involving 240 patients across 23 sites in the United States and Canada. This rigorous trial was designed to evaluate the safety and efficacy of the Urocross system against a control group.
Demonstrating Efficacy and Safety
Clinical results demonstrated substantial and sustained benefits for patients treated with the Urocross system. Twelve months after implantation, patients experienced a mean improvement of 48.1% in their International Prostate Symptom Score (IPSS). Furthermore, the procedural responder rate was 74.5%, meeting the FDA's definition for a clinically meaningful improvement in symptoms.
The safety profile of the Urocross system was a key highlight of the clinical data, with no device or procedure-related serious adverse events reported. Importantly, the treatment demonstrated a preservation of sexual function, as no patients reported new, sustained erectile or ejaculatory dysfunction. The procedure's tolerability was also noted to be high, comparable to that of a standard diagnostic flexible cystoscopy.
Expert Endorsement for Early Intervention
Leading urologists involved in the trial emphasized the technology's potential to shift BPH management toward earlier intervention. Dr. Kevin T. McVary noted that BPH is a bladder health issue and that non-permanent options like Urocross provide effective relief while preserving sexual function. This approach may encourage patients to seek treatment sooner, potentially preventing irreversible bladder damage over time.
Dr. Daniel B. Rukstalis added that BPH care is a long-term commitment, making the preservation of future options crucial. He highlighted that technologies avoiding permanent implants are becoming increasingly relevant in clinical decision-making for chronic diseases. This positions Urocross as a potential first-line interventional therapy, even before considering long-term medications for some patients.
Strategic Launch and Company Outlook
Prodeon Medical's President, Thomas Palermo, described the FDA clearance as a significant milestone for the company. He stated that Urocross introduces a new class of retrievable intervention designed to balance durable symptom relief with patient preferences. The company plans to initiate a controlled commercial release of the system in the United States later this year.
The FDA clearance of the Urocross Expander System represents a meaningful evolution in the treatment landscape for benign prostatic hyperplasia. By offering a safe, effective, and minimally invasive solution that remodels tissue without leaving a permanent implant, Prodeon Medical provides a valuable new option for patients and clinicians. This technology addresses the immediate need for symptom relief while thoughtfully preserving a patient's future healthcare options.